Biomea Fusion, Inc. Stock Price, News & Analysis

Biomea Fusion (Nasdaq: BMEA) presented new preclinical data on BMF-219, a covalent menin inhibitor, at the EASD Annual Meeting in Stockholm, demonstrating its ability to improve pancreatic beta cell function and glycemic control in a diabetic rat model. Over 4 weeks, BMF-219 significantly reduced HbA1c by 3.5% compared to liraglutide's 1.7%, along with improvements in fasting glucose and weight loss. The company aims to file an IND for BMF-219 in Type 2 Diabetes by late 2022, showcasing its potential as a disease-modifying oral treatment.

Biomea Fusion presented significant findings at the 19th International Myeloma Society Annual Meeting (August 25-27, 2022). BMF-219 demonstrated robust anti-tumor activity, achieving over 90% inhibition in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple myeloma (MM). The ongoing Phase I clinical trial, COVALENT-101, aims to explore BMF-219’s effects on patients with relapsed/refractory cancers. The preclinical results underscore BMF-219’s potential as a first-in-class menin inhibitor, indicating a promising future for its clinical applications.

Biomea Fusion (Nasdaq: BMEA) reported significant advancements in its clinical pipeline, focusing on BMF-219, a covalent menin inhibitor. The COVALENT-101 Phase I study is enrolling patients for various malignancies, with IND submissions for solid tumors and type 2 diabetes expected soon. Financial results show a net loss of $33.6 million for H1 2022, up from $14.3 million in H1 2021, primarily due to increased R&D expenses. Cash reserves stand at $150.2 million, down from $175.7 million at year-end 2021, indicating ongoing investment in product development and operational expansion.

Biomea Fusion (BMEA) announced significant findings from two oral presentations at the EASD Annual Meeting, showcasing its drug BMF-219. The preclinical studies reveal that BMF-219, a covalent menin inhibitor, achieves a 50% reduction in blood glucose levels and a notable 3.5% reduction in HbA1C, surpassing existing treatments like liraglutide. This novel treatment maintains glycemic control even after treatment cessation. The company plans to initiate a Phase I/II clinical trial in the second half of 2022, pending IND submission and clearance.

Biomea Fusion announced the first patient dosing in its Phase I clinical trial, COVALENT-101, evaluating BMF-219, a covalent menin inhibitor, for relapsed/refractory multiple myeloma (MM). This marks BMF-219 as the first menin inhibitor targeting MM. The trial has expanded to include cohorts for both MM and diffuse large B-cell lymphoma (DLBCL), while patient enrollment continues for acute leukemia cohorts. Approximately 35,000 new MM cases are diagnosed annually in the U.S., with a notably low 5-year survival rate of ~56% for affected patients.

Biomea Fusion has reported promising preclinical results for BMF-219, a covalent menin inhibitor, showcasing its potential in treating type 2 diabetes. In studies involving ZDF and STZ rat models, BMF-219 demonstrated significant improvements in glycemic control and reduced HbA1c levels, outperforming standard treatments like pioglitazone and liraglutide.

The company plans to initiate a Phase I/II clinical trial in the second half of 2022, contingent on IND submission and clearance, aiming to explore BMF-219's long-term efficacy in diabetes management.

Biomea Fusion, a clinical-stage biopharmaceutical company (Nasdaq: BMEA), announced CEO Thomas Butler's participation in the Jefferies Healthcare Conference on June 8, 2022, at 2:30 PM ET. The event will feature a fireside chat where Butler will discuss the company's innovative approach to developing covalent small molecules aimed at treating genetically defined cancers and metabolic diseases. A live webcast of the chat will be available for 90 days post-event at Biomea Fusion Investors.

Biomea Fusion (Nasdaq: BMEA) announced its participation in the American Diabetes Association Scientific Sessions, presenting pre-clinical data on BMF-219, a covalent menin inhibitor, as a potential treatment for type 2 diabetes. The presentations on June 5, 2022, highlighted BMF-219's significant and durable reduction in HbA1c levels in diabetic rat models, suggesting improved beta cell function and glycemic control compared to liraglutide. A virtual investor event on June 6 will further discuss BMF-219’s therapeutic prospects.

Biomea Fusion (BMEA) announced significant findings related to BMF-219, a novel menin inhibitor effective against chronic lymphocytic leukemia (CLL). In preclinical studies, BMF-219 demonstrated over 98% cell lethality across various CLL tumor models, particularly in high-risk patient samples with TP53 alterations and NOTCH1 mutations. Moreover, BMF-219 showed superior activity compared to standard treatments like bendamustine and ibrutinib. Currently, it is undergoing a Phase I trial (COVALENT-101) for multiple hematologic malignancies, highlighting its potential to address unmet clinical needs.